Voyager co-founder Steven Paul steps down from CEO seat; Alnylam enters final stretch at the FDA with patisiran
→ Voyager Therapeutics $VYGR is hunting for a new CEO as co-founder and current chief executive Steven Paul has decided to focus on preclinical discovery research and portfolio development. After six years on the front line, he will transition to the role of executive science advisor and stay on both the board and the science & tech committee. Paul, an Eli Lilly vet, was a venture partner at Third Rock when he helped form the biotech, known for its gene therapy for Parkinson’s disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.